The Pilocarpus microphyllus Stapf ex Wardlew specie is a native plant from north and northeast of Brazil occurring in eastern of Pará state, northwest and north of Maranhão and Piauí. It is one of the most important Brazilian medicinal species presents in pharmacopoeia of the entire world due to the use of its active pilocarpine. When using the Web of Science periodic base with Pilocarpus genus the result was 56 articles and for the specie Pilocarpus microphyllus the result found was 17 articles. The search for patents was using the basic patent Derwent Innovation Index, INPI, EPO and USPTO getting a contrasting result with the number of articles, recital Japan highlighted in protection of research involving Pilocarpus. The genus Pilocarpus with emphasis on Pilocarpus microphyllus specie through published articles and patents granted in Brazil and in other countries highlights the economic and industrial importance of the specie and provides future perspectives in the discovery of new pharmacological and biotechnological applications of the others alkaloids which so far remains unknown.

The Boophilus Microplus tick is responsible for causing large losses in cattle, its control is based on the use of chemical products and this species has presented an increasingly resistance to the products used. The objective of this article is to evaluate the technological profile for the control of the Boophilus Microplus tick through a patentometric study. In order to identify the study, we used the patents of Espacenet and Derwent Innovations Index, where 514 patents were found and 245 were analyzed. The Vantage Po int® software was used to identify the temporal evolution, the collaborative network between the researchers and the geographical distribution. It was concluded that the studies identified are of great relevance for the control of ticks, considering that technological publications are important markers of production activity and development of the field of knowledge Keywords-control, patentometry, patents, technological production, ticks.

No abstract

: Targeted therapy has been recently highlighted due to the reduction of side effects and improvement in overall efficacy and survival to different types of cancers. Considering the approval of many monoclonal antibodies in the last twenty years, cancer treatment can be accomplished by the combination of monoclonal antibodies and small molecule chemotherapeutics. Thus, strategies to combine both drugs in a single administration system are relevant in the clinic. In this context, two strategies are possible and will be further discussed in this review: antibody-drug conjugates (ADCs) and antibody-functionalized nanoparticles. First, it is important to better understand the possible molecular targets for cancer therapy, addressing different antigens that can selectively bind to antibodies. After selecting the best target, ADCs can be prepared by attaching a cytotoxic drug to an antibody able to target a cancer cell antigen. Briefly, an ADC will be formed by a monoclonal antibody (MAb), a cytotoxic molecule (cytotoxin) and a chemical linker. Usually, surface-exposed lysine or the thiol group of cysteine residues are used as anchor sites for linker-drug molecules. Another strategy that should be considered are antibody-functionalized nanoparticles. Basically, liposomes, polymeric and inorganic nanoparticles can be attached to specific antibodies for targeted therapy. Different conjugation strategies can be used, but nanoparticles coupling between maleimide and thiolated antibodies or activation with the addition of ethyl-3-(3-dimethyl aminopropyl) carbodiimide (EDC)/ N-hydroxysuccinimide (NHS) (1:5) and further addition of the antibody are some of the most used strategies. Herein, molecular targets and conjugation strategies will be presented and discussed to better understand the in vitro and in vivo applications presented. Also, clinical development of ADCs and antibody-conjugated nanoparticles were addressed in the clinical development section. Finally, due to the innovation related to the targeted therapy, it is convenient to analyze the impact on patenting and technology. Information related to temporal evolution of number of patents, distribution of patent holders and also the number of patents related to cancer types are presented and discussed. Thus, our aim is to provide an overview in the recent developments in immunoconjugates for cancer targeting and highlight the most important aspects for clinical relevance and innovation.

A Bioprospecção se tornou uma das principais discussões nos últimos anos desde a Convenção sobre Diversidade Biológica (CDB), no entanto, as informações obtidas no banco de dados da Web of Science demonstraram que o estudo neste tema não se restringe aos